View Older Stories View More Recent Stories

Oct 20, 2023 08:00AM AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Oct 19, 2023 04:00PM AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
Oct 16, 2023 09:00AM AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
Oct 6, 2023 08:30AM Amgen (AMGN) Completes Acquisition of Horizon Therapeutics
Oct 6, 2023 08:30AM AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
Sep 20, 2023 04:00PM AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
Sep 11, 2023 04:00PM AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Sep 11, 2023 05:43AM Amgen (AMGN) Reports New LUMAKRAS Plus Chemo Data
Sep 10, 2023 09:00AM AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
Sep 7, 2023 04:00PM AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
Sep 1, 2023 09:21AM Horizon Therapeutics (HZNP) and Amgen (AMGN) Resolve FTC Lawsuit, Clear Path to Close Acquisition
Sep 1, 2023 09:20AM Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
Aug 31, 2023 07:30PM AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
Aug 28, 2023 05:09AM Amgen (AMGN) Presents Data from Phase 2 OCEAN(a)-DOSE study of olpasiran
Aug 26, 2023 10:45AM AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
Aug 21, 2023 04:01PM Amgen (AMGN) To Discuss Application For Lumakras For The Treatment Of KRAS G12C-positive NSCLC At FDA Advisory Committee Meeting
Aug 21, 2023 04:00PM AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Aug 3, 2023 04:01PM AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
Aug 1, 2023 04:00PM AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
Jul 31, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
Jun 21, 2023 09:01AM Amgen (AMGN) Announces Full FDA Approval of BLINCYTO
Jun 21, 2023 09:00AM FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Jun 9, 2023 04:00PM AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Jun 4, 2023 08:00AM AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
Jun 1, 2023 09:00AM AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
May 30, 2023 06:00PM AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
May 26, 2023 04:00PM AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
May 18, 2023 08:00AM Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 16, 2023 11:32AM Amgen (AMGN) Responds To FTC Action Regarding Proposed Acquisition Of Horizon Therapeutics (HZNP)
May 16, 2023 11:31AM AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
May 9, 2023 09:02AM Amgen (AMGN) And Tscan Therapeutics (TCRX) Announce Collaboration To Identify Novel Targets In Crohn's Disease
May 9, 2023 09:00AM Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 9, 2023 09:00AM AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
May 8, 2023 09:02AM Amgen (AMGN) Reports New PROLIA Data Showing Reduction in Osteoporotic Fracture Risk Compared to Alendronate
May 8, 2023 09:00AM NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
May 5, 2023 04:27PM AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
May 3, 2023 04:00PM AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Apr 27, 2023 04:01PM AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
Apr 21, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
Apr 19, 2023 04:45PM Amgen (AMGN) Wins Patent Appeal On Otezla
Apr 19, 2023 04:45PM AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
Apr 6, 2023 06:15PM ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
Mar 23, 2023 08:34PM AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
Mar 9, 2023 05:20PM AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE
Mar 7, 2023 04:00PM AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
Mar 3, 2023 04:00PM AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE
Mar 1, 2023 09:00AM AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Feb 22, 2023 09:04AM Amgen (AMGN) Announces Cardiovascular Study To Evaluate Association Between Lipoprotein And Cardiovascular Risk In African Americans
Feb 22, 2023 09:00AM AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
Feb 14, 2023 05:20AM Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon
View More Recent Stories View Older Stories